CG Oncology expands gene therapy BLA to include broader NMIBC indications

  • <<
  • >>

CG Oncology plans to broaden its initial BLA for its genetically engineered oncolytic adenovirus, cretostimogene grenadenorepvec, to include patients with high-grade papillary-only non-muscle-invasive bladder cancer (NMIBC), following FDA feedback.

The expanded submission will cover the full spectrum of BCG-unresponsive NMIBC, including patients with carcinoma in situ (CIS), with or without papillary tumors, and those with high-grade papillary-only disease. The company expects to complete the submission by the end of March 2027.

The regulatory update coincided with positive topline results from PIVOT-006, a phase 3 trial evaluating intravesical cretostimogene as an adjuvant treatment following complete tumor resection in patients with intermediate-risk and high-grade Ta NMIBC. The trial met its primary endpoint, with cretostimogene reducing the risk of recurrence by 68% compared with surveillance. Median follow-up was 17 months.

Cretostimogene was generally well tolerated, with no Grade 3 or higher treatment-related adverse events or treatment-related discontinuations. PIVOT-006 enrolled 367 patients across approximately 90 sites in the U.S. and Canada. The findings will support a second BLA submission covering intermediate-risk and high-grade Ta NMIBC, which CG Oncology anticipates filing in the second quarter of 2027.

Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy designed to target bladder cancer. It has received FDA fast track and breakthrough therapy designations for BCG-unresponsive NMIBC.

Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox! Sign up now!

More news